Sign in
CompletedNo phase

Clinical and Economic Impact of Herpes Zoster in Cancer Patients

Key facts

Who runs it
AC Camargo Cancer Center
Where
Brazil1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
150 people enrolled
Started
1 Sept 2019
Ended
30 Dec 2024
Type of study
Observational
Treatments tested
  • Herpes Zoster episode
Record updated
19 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Adults (≥18 years)
  • Active solid or hematologic malignancy
  • Evaluation at A.C. Camargo Cancer Center (São Paulo, Brazil) between September 2019 and December 2024
  • Clinically confirmed episode of herpes zoster (initial episode or recurrence)
  • Herpes zoster diagnosed based on a typical painful dermatomal rash with polymorphic lesions (macules, papules, vesicles, and crusts), either localized or disseminated

Who cannot take part

  • No evidence of active malignancy (complete remission or no oncologic treatment for at least one year)
  • Age <18 years
  • Patients in whom herpes zoster was not confirmed after medical record review

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Herpes zoster (HZ) is an important infectious complication among patients with cancer, particularly in the setting of treatment-related immunosuppression. This retrospective observational cohort study aimed to characterize the clinical profile of HZ episodes and estimate direct hospital costs associated with emergency department visits and hospitalizations in patients with active malignancy treated at a Brazilian tertiary cancer center. The study also explored associations between cancer characteristics, recent oncologic therapies, and clinical outcomes, including postherpetic neuralgia, recurrence, disease dissemination, and hospital costs. Findings are intended to support future budget impact and cost-effectiveness analyses of herpes zoster vaccination in oncology populations.

The group in the trial

  • Patients with Herpes Zoster and Active Cancer

    Adult patients with active solid or hematologic malignancies who presented with a clinically confirmed episode of herpes zoster between September 2019 and December 2024 at A.C. Camargo Cancer Center, São Paulo, Brazil.

    Treatment: Herpes Zoster episode

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical and Economic Impact of Herpes Zoster in Cancer Patients - A Retrospective Cohort Study in a Brazilian Cancer Center
Record updated
19 August 2026